A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

• TQA3605 tablets Placebo (Drug): Placebo contains no active substance.
• TQA3605 Tablets (Drug): TQA3605 tablets is core protein allosteric modulators
• Entecavir dispersible tablets (Drug): Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.

Primary outcomes

• hepatitis B virus (HBV) DNA <10 IU/mL [48 weeks]: Percentage of subjects with HBV DNA below the lower limit of quantification (<10 IU/mL) after 48 weeks of treatment.

Secondary outcomes

• Percentage of subjects with HBV DNA<10 IU/mL [12 weeks, 24 weeks, 36 weeks, 60 weeks, 72 weeks]: Percentage of subjects with HBV DNA<10 IU/mL at week 12, 24, 36, 60, and 72
• Percentage of HBV DNA<20 IU/mL [12 weeks, 24 weeks, 36 weeks, 48weeks, 60 weeks, 72 weeks]: Percentage of subjects with HBV DNA<20 IU/mL at weeks 12, 24, 36, 48, 60, and 72 of treatment.
• Percentage of subjects with HBeAg serologic clearance and/or serologic conversion [24weeks, 48 weeks, 72 weeks]: Percentage of subjects with HBeAg serologic clearance and/or serologic conversion
• Alanine aminotransferase(ALT)≤The upper limit of the normal reference value (ULN) [24weeks, 48 weeks, 72 weeks]: The rate of ALT normalization at weeks 24, 48, and 72 of treatment
• Virology breakthrough percentage [24weeks, 48 weeks, 72 weeks]: Percentage of subjects who experienced virological breakthroughs at weeks 24, 48, and 72 of treatment
• Actual values of HBV markers and changes over time relative to baseline [12 weeks, 24 weeks, 36 weeks, 48 weeks, 72 weeks]: Actual values of HBsAg, HBeAg, HBV DNA, HBV RNA, and Hepatitis B core-related antigen (HBcrAg) at each visit time point and their changes over time relative to baseline.
• Adverse events (AE) [72 weeks]: The incidence and severity of adverse events.
• Steady state minimum concentration (Cmin,ss) [48 weeks]: Cmin,ss of TQA3605 and its metabolite

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* 18-65 years old (including boundary values), regardless of gender;
* Screening requires virological , clinical or pathological evidence of hepatitis B virus infection for more than 6 months; HBsAg positive, HBeAg positive, ALT≤5×ULN at screening;
* Never received nucleoside (acid) analog or interferon treatment, or previously received no more than 12 weeks of treatment but had discontinued therapy at least 6 months prior to the screening visit;
* Ability to communicate effectively with researchers and understand and comply with the requirements of this study, understand and sign the informed consent form;
* Male subjects with female partners who have fertility or female subjects of childbearing age are willing to voluntarily adopt effective contraceptive measures screening to within 3 months after leaving the group.

Exclusion Criteria:

* Pregnant (positive pregnancy test) or lactating women.
* Co-infection with other viruses such as Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Human Immunodeficiency Virus (HIV), Syphilis, etc.;
* History of cirrhosis or evidence of significant fibrosis or cirrhosis before or during screening;
* History of hepatocellular carcinoma (HCC) or suspected HCC before or during screening.;
* History of malignant tumors within the past 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection;
* Subjects with other chronic liver diseases, including but not limited to autoimmune liver disease, alcoholic liver disease, Wilson's disease, Gilbert syndrome, etc;
* Previous organ or bone marrow transplantation;
* Clinically significant abnormal laboratory test results at screening.
* Poorly controlled thyroid diseases or clinically significant thyroid dysfunction;
* Autoimmune diseases;
* Significant systemic or major illnesses other than liver disease.
* Any systemic anti-tumor or immunosuppressive therapy, or immunomodulatory therapy within 6 months prior to screening.
* High-dose systemic corticosteroids use within 3 months prior to screening;
* History of alcohol or drug abuse within the past year or excessive alcohol consumption.
* History of blood transfusion within 2 months prior to screening;
* History of allergy to investigational drug or its excipients.
* Previously participated in the clinical trial of hepatitis B core protein allosteric modulators;
* Participation in another clinical trial and receipt of an investigational drug within the following timeframes before the first dose in this study: 5 half-lives (if known) or twice the duration of the biological effect of the study treatment (if known), whichever is longer, or 90 days (if the half-life or duration is unknown);
* History or condition of cardiovascular disease;
* Any other condition deemed inappropriate for inclusion by the investigator.